The nation of Zimbabwe has declined a substantial American health deal valued at $367m (272 million pounds) over five years due to Washington's demand for confidential information.
This move was revealed after a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "skewed".
An official representative has since explained that the United States was demanding access to health data for scientific study and commercial purposes but was unwilling to guarantee the benefits from future treatments.
"We will now turn to the difficult and regrettable task of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had donated over $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more negotiations to reach a agreement agreeable to all parties so the nation's vital HIV treatment initiative can be sustained.
Broader Background
Zimbabwe's decision follows a comparable situation in Kenya, where a court suspended a related health funding agreement after concerns were filed about the safety of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government agreements to boost transparency and responsibility.
As per reports, 16 African countries have so far signed these new health pacts, representing more than $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration would have delivered significant advantages for Zimbabwean communities, especially the 1.2 million currently on antiretroviral therapy through American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to surrender its genetic material and health information for a long time, with no corresponding promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"Put simply, our nation would provide the basic resources for medical research with no certainty that the end products would be available to our population if a new disease outbreak emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one deals were upending systems already established through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing system designed to manage future pandemics.
"This system is designed to ensure that when a country contributes its samples, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome further discussions with our US partners on how subsequent collaboration might be designed in a manner that respects the independence and interests of both nations."
Medical Community Reaction
Medical experts stated it acknowledged the government's concerns, but urged that negotiations must proceed considering much of the country's HIV programmes were funded by international support.
"Where specific concerns exist, such as those relating to data governance or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," it commented.
The halted deal highlights the continuing tensions between receiving much-needed international aid and protecting local interests in an increasingly interconnected world.